A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Acute lymphoblastic leukaemia; Burkitt's lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 09 Aug 2017 Results published in the Blood
    • 19 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 05 Jan 2015 Planned End Date changed from 1 Apr 2017 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top